Company Overview
LENZ Therapeutics is a pharmaceutical company focused on the commercialization of VIZZ (aceclidine ophthalmic solution) 1.44% for the treatment of presbyopia.
Key Financial Figures
For the fourth quarter and year ended December 31, 2025, LENZ reported net product sales revenue of $1.6 million. The company reported a basic and diluted net loss per share of $1.16 per share for the fourth quarter, and $2.85 per share for the full year 2025.
Additional Financial Insights
As of December 31, 2025, cash, cash equivalents, and marketable securities were $292.3 million. Selling, general, and administrative (SG&A) expenses were $91.1 million for the year ended December 31, 2025, driven primarily by preparations for and the execution of the commercial launch of VIZZ.